|Bid||1.7700 x 1000|
|Ask||1.8200 x 1100|
|Day's range||1.7500 - 1.8400|
|52-week range||1.7300 - 5.8900|
|Beta (5Y monthly)||0.24|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Nanalysis Scientific Corp. (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1) ("Nanalysis" or the "Company") is pleased to announce that it has successfully closed the previously announced acquisition of K'(Prime) Technologies Inc. (KPrime), a North American sales and service company, with a particular focus on scientific instrumentation for pharma, food, chemical and oil & gas customers, as well as imaging systems for security applications.
CALGARY, Alberta, Jan. 10, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce its participation in the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10th through 13th, 2022. At the conference, Dr. Allen Davidoff, XORTX’s CEO will provide an update on the Company w
Nanalysis Scientific Corp. (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1) ("Nanalysis" or the "Company") is pleased to announce that, effective December 21, 2021, it has established a Scientific Advisory Board, with four world renowned scientists as founding members, including Dr. Matt Rosen of Harvard Medical School and co-founder of Hyperfine.